Pain treatment biotech Egalet sets terms for $42 million IPO

By
A A A

Egalet, which is developing abuse-deterrent oral products for the treatment of pain, announced terms for its IPO on Thursday. The Malvern, PA-based company plans to raise $42 million by offering 3.5 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Egalet would command a market value of $167 million.

Egalet, which was founded in 1995, plans to list on the NASDAQ under the symbol EGLT. Egalet initially filed confidentially on September 17, 2013. Stifel and JMP Securities are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: EGLT

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Tiny Homes With Big Appeal
Tiny Homes With Big Appeal          

Stocks

Referenced

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com